Skip to content

Pharmacokinetic study of single oral administration of Maobushisaishinto.

Pharmacokinetic study of single oral administration of Maobushisaishinto (TJ-127) in healthy adults.

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080225096
Enrollment
8
Registered
2020-02-28
Start date
2020-03-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy adults

Interventions

investigational material(s) Generic name etc : Tsumura Maobushisaishinto extract granules for ethical use INN of investigational material : - Therapeutic category code : 52- Chinese medicines Dosage a

Sponsors

Tsumura & Co.
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: (1)Japanese (2)Subjects body mass index is between 18.5 and 25.0. (3)Willing and able to provide written, signed informed concent.

Exclusion criteria

Exclusion criteria: (1)Subjects with a history of allergic reactions to drugs and foods. (2)Subjects who have participated in other clinical trial within the past 16 weeks starting from the hospitalization date (two days before test drug administration). (3)Subjects who have had their blood drawn or donated >400mL of blood within the past 12 weeks starting from the hospitalization date (two days before test drug administration). (4)Subjects with a history of significant organopathy. (5)Subjects with a history of digestive disease. (peptic ulcer, reflux esophagitis etc.)(excepting for the history of appendicitis) (6)Subjects with a history of digestive tract resection. (excepting for appendicitectomy) (7)Subjects who cannot quit drinking or smoking from the hospitalization date (two days before test drug administration) to the leaving hospital. (8)Subjects who cannot interrupt drugs other than the test drug or supplements from 7 days before test drug administration to the end of the clinical trial. (9)Subjects with abnormal clinical laboratory values inappropriate for the study in the opinion of the principal investigator/subinvestigator. (10)Subjects who have any of positive HCV antibody, HBs antigen, HIV antigen antibody, TP antibody. (11)Subjects who are deemed ineligible for other reasons by the principal investigator/subinvestigator.

Design outcomes

Primary

MeasureTime frame
safety exploratory pharmacokinetics Ephedrine etc.

Secondary

MeasureTime frame
exploratory pharmacokinetics Other than primary outcome.

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026